Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies.TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding. Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Phosphoinositide 3 kinase enhancer (PIKE) is a recently identified nuclear GTPase that interacts with nuclear phosphoinositide 3-kinase (PI3 kinase) to stimulate its lipid kinase activity. PIKE exists in multiple isoforms; a shorter C-terminal isoform (PIKE-A) has also been identified as centaurin gamma 1. The longest isoform (PIKE-L) has been shown to bind to the adaptor protein Homer and thereby link to metabotropic glutamate receptors, leading to activation of PI3 kinase activity and prevention of neuronal apoptosis. Overexpression of PIKE-A enhances Akt activity and promotes cancer cell invasion, whereas decreased expression of PIKE-A via dominant negative expression of PIKE-A or PIKE-A knockdown inhibits these processes. In many human cancers, expression of PIKE-A is enhanced, leading to increased Akt activity and preventing apoptosis. Also known as: ArfGAP with GTPase domain, ankyrin repeat and PH domain 2.
|Gene Name:||ArfGAP with GTPase domain, ankyrin repeat and PH domain 2|
|Family/Subfamily:||Ras GTPase superfamily IPR001806 , not assigned-Ras GTPase superfamily IPR001806|
|Synonyms:||AGAP2, AGAP-2, Centaurin, gamma 1, Cnt-g1, Centaurin-gamma-1, KIAA0167, GGAP2, PIKE, CENTG1|
|Target Sequences:||NM_014770 NP_055585.1 Q99490|
If you do not find the reagent or information you require, please contact firstname.lastname@example.org to inquire about additional products in development.